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Case presentations
Patient 1. A 62-year-old white woman with adult-onset diabetes
mellitus for 15 years was admitted to Vanderbilt University Hospital for
management of hypertension and renal failure. She had presented to her
local physician with headache and worsening of her previously modest
hypertension; her blood pressure was 240/110 mm Hg. After being
admitted to a local hospital for blood pressure control, she received
sodium nitroprusside intravenously for acute management, followed by
an oral regimen that included clonidine, 0.3 mg three times daily;
captopril, 50mg three times daily; hydralazine, 75 mg three times daily;
and furosemide, 40 mg twice daily. On presentation to the local
hospital, the BUN and creatinine were 47 mg/dl and 2.5 mg/dl,
respectively. Her blood pressure responded to therapy, but the
azotemia worsened and oliguria ensued. She was then transferred to
Vanderbilt University Hospital.
The patient had had a right nephrectomy in 1982 because of transi-
tional-cell carcinoma of the renal pelvis. Hypertension, present for a
number of years, had been more difficult to control since the nephrec-
tomy. The patient's BUN and creatinine were 14 mg/dl and 1.4 mg/dl 20
months prior to the current admission.
Physical examination on admission included a blood pressure of
220/85 mm Hg; respirations, 18/mm; pulse, 78 beats/mm; and temper-
ature, 98.4°F. The patient was alert and in no distress. Pertinent
physical findings included moderate arteriovenous nicking, with no
hemorrhages or exudates apparent on funduscopic examination. Aus-
cultation of the lungs disclosed right basilar rales. Bilateral carotid
bruits were audible. The patient had a grade 1/VI systolic ejection
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murmur at the lower left sternal border and an apical S4 gallop. All
peripheral pulses were 2+ bilaterally. Abdominal and neurologic exam-
inations were unremarkable. No abdominal bruit was noted.
A plain chest film showed cardiomegaly but no other abnormalities.
Electrocardiogram demonstrated normal sinus rhythm with nonspecific
ST-T wave changes. Other pertinent laboratory data on admission
included a serum sodium of 130 mEq/liter; potassium, 4.5 mEq/liter;
chloride, 96 mEq/liter; and carbon dioxide, 21 mEq/liter. The admission
BUN was 91 mg/dl and the creatinine was 6.9 mg/dl. Hematocrit on
admission was 37%. Sonography of the solitary left kidney demon-
strated it to be of normal size with no evidence of obstruction. The
patient was oliguric, and over the next 3 days the BUN rose to 150
mg/dl and the serum creatinine to 13.5 mg/dl. A hemodialysis catheter
was placed in a subclavian vein, and hemodialysis was begun. Three
days later she underwent an intra-arterial digital subtraction aortogram
and renal arteriogram, which demonstrated very tight stenosis of the
left renal artery. Four days later a left renal endarterectomy with a
Gore-Tex patch closure of the arteriotomy was performed without
complication. Over the next 3 days, the serum creatinine fell progres-
sively to 7.4 mg/dl, 4.0 mg/dl, and 2.9 mg/dl. Eighteen months after
surgery, the BUN was 28 mg/dl and the serum creatinine 1.4 mg/dl. Her
blood pressure currently is well controlled with only a calcium-channel
blocker and low doses of furosemide.
Patient 2. A 38-year-old black male was first admitted to the
Nashville Veterans Administration Hospital 3 years ago for accelerated
hypertension. He had not been hospitalized before, and his only
previous medical problem was hypertension discovered 6 years earlier.
After approximately 2 years of treatment with methyldopa and furose-
mide, he discontinued taking his medications. His admission was
prompted by the incidental finding of severe hypertension when he was
seen for treatment of an upper respiratory tract infection.
The patient's mother was hypertensive. There was no family history
of myocardial infarction, cerebrovascular accident, or congestive heart
failure. The patient had smoked one pack of cigarettes per day for many
years.
Physical examination revealed a blood pressure of 180/120 mm Hg;
pulse, 68 beats/mm; respiration rate, 16/mm; nd normal temperature.
Funduscopy disclosed arteriolar narrowing and arteriovenous nicking
without hemorrhages or exudates. Cardiovascular examination re-
vealed normal jugular venous pressure but a laterally displaced and
prominent point of maximal impulse. No murmurs or gallops were
heard. The lungs were clear, and the abdominal examination revealed
no abnormalities. The genitourinary and neuromuscular examinations
were normal.
Pertinent laboratory tests included a normal chest x-ray; an electro-
cardiogram demonstrating left ventricular hypertrophy; a BUN of 7
mg/dl; creatinine, 1.4 mg/dl; sodium, 144 mEq/liter; potassium, 4.3
mEq/liter; chloride, 103 mEq/liter; carbon dioxide, 26 mEq/liter; and
cholesterol, 173 mg/dl. Urinalysis showed a pH of 5, trace protein, and
was negative for blood; microscopy was normal. The 24-hour urine
protein was 59 mg; calculated creatinine clearance was 110 mI/mm.
The hypertension was treated with increasing doses of clonidine,
hydralazmne, and furosemide and with a low-salt diet. The blood
pressure was not particularly difficult to control, and the patient was
discharged within a few days on clonidine, 0.3 mg twice daily;
hydralazine, 100 mg twice daily; furosemide, 20 mg every morning; and
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Table 1. Clinical presentation of ischemic renal disease
1. Acute renal failure, frequently precipitated by a reduction in blood
pressure (i.e., angiotensin-converting-enzyme inhibitors plus di-
uretics)
2. Progressive azotemia in a patient with known renovascular hyper-
tension treated medically
3. Progressive azotemia in a patient (usually elderly) with refractory
hypertension
4. Unexplained progressive azotemia in an elderly patient
5. Hypertension and azotemia in a renal transplant patient
fell to 24 mg/dl and 2.1 mg/dl and reached a nadir of 12 mg/dl and 1.3
mgldl approximately one month after surgery. Currently the patient has
a BUN and creatinine of 10 mg/dl and 1.2 mg/dl. The blood pressure is
adequately controlled (diastolic pressure <90 mm Hg) with minoxidil,
10 mg twice daily; clonidine, 0.1 mg twice daily; atenolol, 50 mg every
morning; and diltiazem, 30 mg three times daily.
Discussion
Fig. 1. Digital subtraction angio gram demonstrating severe bilateral
renal artery stenosis.
potassium chloride elixir, 40 mmol every morning. Followup by the
hypertension service was arranged.
Over the next 2 years, the patient's hypertension became more
difficult to control and required the addition of captopril, 50 mg three
times daily, and minoxidil, 10 mg twice daily, in place of hydralazine.
Also, the furosemide dose was increased to 40 mg twice daily.
One year ago, the patient was readmitted to the hospital with
accelerated hypertension and symptoms of congestive heart failure. At
that time, the blood pressure was 180/110 mm Hg and the physical
examination was unchanged from the previous admission save for the
presence of an S4 gallop and trace pedal edema. However, chest x-ray
showed cnrdiomegaly, and an electrocardiogram demonstrated left
ventricular hypertrophy with strain. The hematocrit was 36%; electro-
lytes were: sodium, 141 mFq/liter; potassium, 4.7 mEq/liter; chloride,
110 mFq/liter; and carbon dioxide, 23 mEq/liter. Glucose was 81 mg/dl;
BUN, 46 mg/dl; and creatinine, 3.0 mg/dl. To treat his hypertension,
nifedipine was added and furosemide was increased to 80 mg twice
daily; the minoxidil dose was increased to 30 mg twice daily.
Renal ultrasound demonstrated normally shaped kidneys bilaterally,
with the left kidney 9.8 cm, and the right 10.4 cm in length. Blood
pressure control required intravenous nitroprusside. Over the first 5
days of hospitalization, the patient's BUN and creatinine increased to
77 mg/dl and 6.6 mg/dl respectively. A 24-hour urine collection for
vanillylmandelic acid, catecholamines, and hydroxy- and ketosteroids
demonstrated normal excretion rates for all of these. A renal blood-flow
study and bilateral renogram using SSMTc pertechnetate and 1311 hip-
purao showed bilateral decreased perfusion and poor function. Intra-
arterial digital subtraction angiography demonstrated bilateral, almost
complete renal artery stenosis (Fig. 1). Three weeks after admission,
with the BUN 131 mg/dl and the creatinine 5.9 mg/dl, the patient was
hemodialyzed. Corrective surgery was planned but postponed because
the patient developed a perforated diverticulum with abscess formation
requiring a sigmoid colectomy and colostomy. He recovered fully and
was discharged.
Nine months ago, the patient underwent bilateral renal artery endar-
terectomy. The BUN and creatinine on admission were 59 mg/dl and 4,6
mg/dl. After surgery, the blood pressure was better controlled but still
required multiple-drug therapy. He was discharged 9 days after surgery
with a blood pressure of 120/80 mm Hg, a BUN of 45 mg/dl, and a
creatinine of 4.2 mg/dl. Over the ensuing days, the BUN and creatinine
DR. HARRY R. JACOBSON (Professor of Medicine, Vanderbilt
University School of Medicine; and Chief, Division of Nephrol-
ogy, Vanderbilt University Medical Center, Nashville, Tennes-
see): These two patients illustrate clinical circumstances asso-
ciated with ischemie renal disease. The first patient had a
solitary kidney and refractory hypertension. Her worsening
hypertension probably resulted from ischemic disease and, as
we will discuss later, critical renal artery stenosis predisposed
her to acute renal failure when aggressive medical management
of hypertension was pursued. The second patient demonstrates
another common way in which ischemic renal disease can
present. This patient had difficult-to-control hypertension and
progressive azotemia. For several years the patient's declining
renal function was thought to be due to poorly controlled
hypertension and secondary hypertensive nephrosclerosis.
Thus, finding severe bilateral renal vascular disease came
somewhat as a surprise to his physicians, especially because
this patient was under the age of 50 years.
Table 1 lists 5 of the more common clinical presentations of
ischemic renal disease. The first patient I presented is an
example of the first clinical presentation, and the second patient
is an example of the third. I will address the second and fourth
clinical presentations listed, but I will not address the fifth,
namely, hypertension and azotemia in the renal transplant
patient.
Before I outline the key questions that this discussion will
address, I would like to define "ischemic renal disease."
Obstruction of blood flow to the kidney is responsible for two
major clinical syadromes. The first is renovascular hyperten-
sion. These patients usually have unilateral, hemodynamically
significant stenosis of the renal artery. They usually do not have
a clinically important reduction in renal function, because the
contralateral kidney generally compensates if the glomerular
filtration rate of the kidney supplied by the stenotic artery is
reduced. Renovascular hypertension was discussed in a previ-
ous Nephrology Forum [11. The second syndrome associated
with renal vascular obstruction is the one that concerns us
today, that is, ischemic renal disease. I define ischemic renal
disease as a clinically significant reduction in glomerular filtra-
tion rate in patients with hemodynamically significant obstruc-
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tion to renal blood flow in the renal artery of a solitary kidney,
or in both renal arteries if two kidneys are present. Ischemic
renal disease can result from a reduction in the caliber of the
renal artery by atherosclerosis, fibromuscular dysplasia, and a
number of rare diseases including dissection of the aorta,
vasculitis (such as Takayasu's arteritis), and embolism to the
renal artery (thromboembolism and cholesterol embolism). I
will focus here on atherosclerotic disease.
With respect to clinically significant ischemic renal disease
due to atherosclerosis, I will address the following questions:
(1) What is the natural history of atherosclerotic renal vascular
disease? (2) Which patients are at risk for the development of
the atherosclerotic variety of ischemic renal disease and who
should be studied? (3) How should patients be evaluated for
ischemic renal disease? (4) After identification of ischemic renal
disease, which patients should be treated medically, which
kidneys should be revascularized, what procedure—surgery or
angioplasty—should be recommended, and are there any pre-
dictors for successful revascularization?
The natural history of atherosclerotic renal vascular disease
Several studies have documented progression of atheroscle-
rosis in renal arteries [2—4]. Most of these data come from
studies of medically treated patients who have documented
renovascular hypertension. In the late 1960s, Wollenweber et a!
reported the clinical course of 109 patients with renal artery
atherosclerosis and the anatomic changes in the renal arteries
(as assessed by serial arteriography) in 30 patients [2]. Although
most of the patients in this group were studied because they
were hypertensive, some underwent arteriography because of
aorto-iliac occlusive disease or the presence of an abdominal
aortic aneurysm. Of these 109 patients, 92% had hypertension,
and their mean age was 54 years. Males outnumbered females
by a ratio of almost 2 to 1. Fifteen percent of the 109 had
azotemia as defined by a BUN greater than 50 mg/dl or a serum
creatinine greater than 2 mg/dl. The mean followup for the
entire group was 42 months. On followup examination, 12% of
the originally nonazotemic patients had developed azotemia,
and an additional 20% had a greater than 15% decrease in
creatinine clearance. Importantly, the estimated 5-year survival
rate of all 109 patients was 66.7%, significantly lower than the
expected survival rate of 91.7% in a comparable normal popu-
lation sample. In this study, howevei, no significant difference
existed between the 5-year survival rates of the patients who
had renal vascular surgery and those who did not, Irrespective
of whether patients were treated surgically or medically, sur-
vival was significantly greater in the patients with well-con-
trolled hypertension. Of note, 52 episodes of symptomatic
atherosclerotic cardiovascular disease were observed in 43
patients during the followup period. Indeed, for the entire
group, the estimated 5-year survivorship free of symptomatic
atherosclerotic cardiovascular disease was only 53.2%.
With respect to the 30 patients who had a second arteriogram,
the mean interval between studies was 28 months. Significant
atherosclerotic disease developed in 3 renal arteries that previ-
ously had not been involved, and the preexisting disease
worsened in 21 arteries. In 2 patients in whom nephrectomy had
been performed, severe narrowing of the contralateral renal
artery developed. The observation that there is a high incidence
of co-existing atherosclerotic disease in various regions of the
body was confirmed by this study. Of the patients with mild or
moderate narrowing of the main renal artery, 31% had clinical
evidence of symptomatic coronary artery, cerebrovascular, or
peripheral vascular disease; 49% of the patients with marked or
severe atherosclerotic renal artery narrowing had evidence of
atherosclerotic disease elsewhere. One final important aspect of
this study is that 84% of the involved renal arteries showed
atherosclerotic plaques at the orifice, in the first third, or both.
The atherosclerotic process involved exclusively the second
third or distal third of the main renal artery in less than 5% of
the renal arteries.
The second important study addressing the natural history of
atherosclerotic renal artery disease came from Dean and col-
leagues in the early 1980s. These investigators evaluated the
results of serial renal function studies on 41 patients with known
renovascular hypertension secondary to atherosclerotic renal
vascular disease and who had been randomly selected for
medical as opposed to surgical management [3]. Patients were
between the ages of 40 and 65 years and demonstrated func-
tionally significant renovascular hypertension, based on results
of split renal function studies or renal-vein renin measurements.
Three criteria were used to assess deterioration in renal status.
These included (1) a decrease in renal length; (2) an increase in
serum creatinine; and (3) a decrease in isotopically determined
GFR. Fourteen patients (35%) had a 10% to 25% reduction in
renal length, whereas 8 patients had a 50% to 100% increase in
serum creatinine, and 2 patients had greater than a doubling of
serum creatinine. Mean followup was 36 months. Thirty pa-
tients had repeat glomerular filtration rates measured during a
followup period of 18 to 24 months. Eleven of these 30 patients
had a 25% to 50% decrease iii GFR, and one patient had a
greater than 50% decrease in GFR. Of note, neither hyperlipo-
proteinemia nor poor blood pressure control correlated with
progression of the renal vascular disease. Indeed, and impor-
tantly, significant deterioration of renal function occurred in
some patients whose blood pressures were well controlled. This
category of patient fits the second clinical presentation in Table
A third important study on the natural history of atheroscle-
rotic renal artery disease comes from Schreiber and coworkers
[4]. These authors retrospectively analyzed all patients who had
had two or more renal angiograms between 1960 and 1979 at the
Cleveland Clinic Foundation. Of the 169 patients identified, 85
had atherosclerotic lesions. The mean interval between angi-
ograms was 52 months. The degree of renal artery stenosis was
categorized as (1) less than 50% stenosis; (2) 50% to 75%
stenosis; (3) 75% to 99% stenosis; or (4) total occlusion.
Angiographic evidence for progression was defined as a change
from one category to another of higher grade. Serial angio-
graphic data then were compared with blood pressure, kidney
size, and overall renal function. Table 2 demonstrates the
progression in these patients: 24 of 78 patients with less than
50% stenosis had greater stenosis on followup; 14 of 30 patients
with 50% to 75% stenosis had worsening disease on followup;
and 7 of 18 patients with 75% to 99% stenosis had complete
occlusion on followup. Thus, of a total of 126 diseased renal
arteries, 45 (36%) demonstrated significant progression. These
authors also demonstrated a correlation between serum creati-
nine or kidney size and progression of the renal artery stenosis.
Blood pressure control did not correlate with progression of
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Table 2. Progression of atherosclerotic renal artery disease°
.% Stenosis on
initial study 50%
% Stenosis on followup
50%—75% 75%—99% 100%
c50%(n 78)b 54 12 8 4
50%—75%(n=30) 16 11 3
75%_.99% (n = 18) 11 7
a From Ref. 4.
n refers to number of arteries.
renovascular stenosis. Although serum creatinine and kidney
size correlated with progression, it is important to note that
one-half of the patients with angiographically proven progres-
sion of renal vascular disease had no significant change in serum
creatinine (that is, a 20% or greater elevation), and 25% of the
patients with no angiographic evidence of progression had an
increased serum creatinine. Similarly, about one-third of the
patients with progression of the renal vascular lesion had no
change in kidney size, whereas one-third of the patients who did
not demonstrate progression of renal vascular disease had a
significant decrease in kidney size (that is, a greater than 10%
decrease in renal length). From this study, the authors sug-
gested that one can define a group of patients with renal
vascular disease who are at increased risk of developing clini-
cally significant decreases in renal function. This group at high
risk includes patients with moderate azotemia and high-grade
renal artery stenosis (between 75% and 99%), patients with
bilateral high-grade arterial stenosis, and patients with signifi-
cant stenosis involving a solitary functioning kidney.
Clinical features that increase the likelihood of
ischemic renal disease
Which patients should be evaluated for ischemic renal dis-
ease? To best answer this question, one must consider the
diagnostic procedures that are utilized and their attendant risks
and complications. In addition, one must consider whether a
given patient will be a candidate for a revascularization proce-
dure if renal vascular occlusive disease is found. I will address
these issues shortly. Table I partly answers the question, who
should be evaluated? Excluding the transplant patient, let us
examine each of the remaining four clinical presentations in
detail.
Over the past 8 years, a characteristic syndrome of acute
renal failure has been defined in patients receiving angiotensin-
converting-enzyme inhibitors [5—12]. This syndrome develops
in patients with stenosis of the renal artery in a solitary kidney
or bilateral renal artery stenosis. Usually these patients develop
acute and reversible renal failure within I to 14 days after the
initiation of antihypertensive therapy with angiotensin-convert-
ing-enzyme inhibitors. These patients generally have few or no
abnormal findings in the urinary sediment and no clinical
evidence of acute tubular necrosis or glomerulonephritis. Fre-
quently, they are receiving not only a converting enzyme
inhibitor, but also a diuretic. There are at least two pathophys-
iologic contributors to renal failure in this syndrome. The first is
hypoperfusion of the kidney due to a major fall in blood
pressure in the setting of critical renal artery stenosis. How-
ever, acute renal failure after administration of a converting
enzyme inhibitor also can occur without a major reduction in
systemic blood pressure. In these patients, it is believed that an
intrarenal hemodynamic change is responsible for the acute
reversible reduction in GFR. Reduction in renal plasma flow
due to fixed obstruction in the main renal artery ordinarily
would be associated with a major reduction in GFR in these
kidneys were it not for the maintenance of high glomerular
capillary pressure by angiotensin Il-mediated constriction of
the efferent arteriole. This angiotensin Il-stimulated constric-
tion of the efferent arteriole is thought to be more pronounced
in patients who are being treated with a diuretic. When the
intrarenal angiotensin II action is blocked by the administration
of a converting enzyme inhibitor, efferent arteriolar vasocon-
striction decreases and glomerular capillary pressure falls. The
fixed obstruction in the main renal artery prohibits any increase
in glomerular plasma flow. Thus GFR falls precipitously. The
frequency with which patients with either severe stenosis in a
solitary kidney or bilateral stenosis develop acute renal failure
varies in different reports. Captopril-induced acute renal failure
was reported in 6% of 136 such patients [13]. In other series,
however, the percentage of patients developing this syndrome
varied from 17% to 23% in patients with bilateral renal artery
stenosis and 38% in patients with renal artery stenosis in a
solitary kidney [14, 15].
Patients given antihypertensive drugs other than angiotensin-
converting-enzyme inhibitors also can develop this syndrome.
Acute renal failure can be precipitated by other agents and
combinations thereof, including thiazide diuretics, clonidine,
beta blockers, alpha-ruethyldopa, minoxidil, calcium-channel
blockers, and intravenous sodium nitroprusside [16, 17]. In-
deed, one group has proposed the use of intravenous nitroprus-
side as a screening tool for the evaluation of hemodynamically
significant renovascular disease affecting renal function [16].
Figure 2 illustrates how hypotensive therapy with a brief
intravenous administration of nitroprusside can be associated
with dramatic reductions in GFR and renal plasma flow [16].
This study was performed in a patient with a totally occluded
left renal artery, with virtually no renal function on the left, and
with significant atherosclerotic stenosis of the distal right main
renal artery. Shown for comparison are the hemodynamic and
renal functional responses to a second administration of sodium
nitroprusside after surgical correction of the right renal artery
stenosis. The study showed that postoperatively (that is, after
correction of the hemodynamically significant obstruction in the
right renal artery) the nitroprusside-induced acute reduction in
systemic blood pressure no longer produced a significant de-
crease in glomerular filtration rate or renal plasma flow.
Although reduction in blood pressure by pharmacologic
means frequently is a precipitating factor in the development of
acute renal failure in these patients, other factors also can be
responsible, including volume depletion from hemorrhage,
vomiting, or diarrhea. In these circumstances, patients can
develop true hypotension and experience not only a reversible
functional renal failure, but even acute tubular necrosis.
What is an appropriate diagnostic approach to these patients?
Patients who have, prior to an episode of acute renal failure
induced by antihypertensive drugs, serum creatinine levels less
than 2 mg/dl and whose creatinine levels return to less than 2
mg!dl should have serial creatinine clearances performed at
3-month intervals, If renal function declines with time, these
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patients should be considered for angiography and revascular-
ization, assuming appropriate lesions are found. In patients
with creatinine levels initially greater than 2 mg!dl, and in
patients who, after an episode of acute renal failure, maintain a
serum creatinine greater than 2 mg/dl, speedier study and
treatment is appropriate. This approach admittedly is empiric.
Indeed, this approach can delay recognition and treatment of
patients with a solitary kidney and renal artery stenosis or
patients with bilateral disease associated with occlusion of one
renal artery. Alternatively, therefore, one could screen all
patients who develop renal failure after antihypertensive ther-
apy. If angiography is not used, ultrasound or nuclear scan
should be employed to determine whether (1) anatomically or
functionally, a single kidney is present; or (2) a significant (>1.5
cm) discrepancy in renal length exists. Also, one should keep in
mind that the decision to study these patients can be affected by
the presence of concurrent hypertension and the ease with
which the blood pressure is controlled.
The second group of patients that should be studied for
ischemic renal disease comprises individuals with progressive
azotemia and known renovascular hypertension who are under
medical management. As I outlined in our discussion of the
natural history of atherosclerosis of the renal arteries, progres-
sive worsening of the stenosis leads to a significant reduction in
creatinine clearance in a sizable number of patients. Indeed,
progressive elevation of the serum creatinine in a patient with
known renovascular disease should be considered due to isch-
emic renal disease until proven otherwise. Remember that
progressive stenosis can occur whether or not the patient's
hypertension is well controlled by medical therapy.
Another, and possibly the largest, group of patients in whom
ischemic renal disease can be the cause of renal failure are those
with renovascular disease and variable degrees of hypertension
who have not been evaluated specifically for renovascular
hypertension. These patients often exhibit clinical features
suggestive of underlying renovascular disease. Some of these
features include: (1) development of hypertension after the age
of 50 years; (2) poor response to antihypertensive therapy or
escape from previous pharmacologic control of hypertension;
(3) accelerated hypertension; (4) history of flank pain and
hematuria and; (5) presence of a flank or abdominal bruit. Thus
a patient with azotemia of unknown cause and no evidence of
glomerular disease (that is, an unremarkable urinary sediment
and a urine protein excretion of less than 1 g124 hours) exhib-
iting any of the features enumerated should be evaluated for
ischemic renal disease.
The final group of patients who may possibly have ischemic
renal disease are elderly patients with unexplained azotemia.
Unexplained azotemia in these patients refers to renal failure
that cannot be attributed to causes such as analgesic abuse,
collagen vascular disease, obstruction, or primary glomerular
disease. These patients generally have a history of hyperten-
sion, although it need not be uncontrolled or refractory. They
often have clinical evidence of significant atherosclerotic dis-
ease in other major vessels. Urinary protein excretion typically
is less than 1 g/24 hours. Indeed, no elderly patient with
unexplained azotemia should be evaluated for ischemic renal
disease until, at a minimum, obstruction has been ruled out and
urine collected for 24-hours for determination of creatinine
clearance and protein excretion.
How should patients be evaluated for ischemic renal disease?
In addressing this question, it is helpful if we focus on the
anatomic variations that can produce ischemic renal disease.
First, for various reasons—either congenital or secondary to
surgical removal—a patient can have an absent or undeveloped
kidney. Second, patients can have two kidneys, with one
kidney having total occlusion of its renal artery and the remain-
ing kidney demonstrating significant stenosis of its renal artery.
Depending on certain characteristics of the occluded kidney,
these patients might or might not have a potential for two
functional kidneys. Third, patients can have bilateral renal
artery stenosis with hypoperfusion of both kidneys. These
patients potentially have two functional kidneys. With these
possibilities in mind, the diagnosis of ischemic renal disease
must involve a series of diagnostic tests that can define the
presence of one or two functional kidneys, the size of both
kidneys, and an accurate depiction of the vascular anatomy. In
addition, the discovery of a renal artery lesion is not always
proof that this lesion is functionally important. Ideally, one
requires additional diagnostic tests to establish whether the
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Table 3. Diagnostic tests for identifying ischemie renal disease
Test Comment
1. Rapid-sequence IVP Not directly helpful. Can be of
incidental benefit in identify-
ing patients with one (or one
functional) kidney
2. Renal ultrasound Not directly helpful. Useful to
exclude lower urinary tract
obstruction. Of incidental
benefit to define renal anato-
my (I or 2 kidneys and renal
size)
3. Isotopic renal blood flow Not directly helpful. Can be
and functional scans useful in followup to deter-
mine patency of repaired
vessels
4. Angiography
a) Intravenous digital May be useful in followup af-
subtraction ter surgery or angioplasty
b) Intra-arterial digital May become procedure of
subtraction choice because of require-
ment for less contrast
media
e) Conventional aortography Currently best test to define
with selective renal renal vascular anatomy
arteriography
5. Supine and stimulated pe- Less helpful than in renovas-
ripheral renin cular hypertension. Not pri-
marily indicated
6. Renal-vein renins Not helpful. Can be useful in
deciding which kidney to re-
vaseularize first in the set-
ting of bilateral stenosis
7. Split renal function Not indicated in diagnostic
workup. Can be useful in
strategy for revasculariza-
tion
8. Acute hypotensive therapy Not prospectively useful in di-
while monitoring OFR and agnosis but occasionally
renal blood flow helpful in formulating thera-
peutic strategy
anatomically defined renal vascular disease is responsible for a
clinically significant (and reversible) reduction in GFR. Table 3
lists the pertinent diagnostic tests with a comment regarding
their application and usefulness. It is important to note that
similarities exist between the evaluation of patients with sus-
pected isehemie renal disease and that of patients with sus-
pected renovaseular hypertension. However, a fundamental
difference exists between these two situations. Renovaseular
hypertension is most commonly associated with at least one
normally functioning kidney; thus, a number of tests can be
employed that involve a comparison of the two kidneys. Iseh-
emic renal disease, on the other hand, involves significant
dysfunction of both kidneys (or of the solitary kidney), so that
none of the tests comparing kidneys is especially useful.
The rapid-sequence intravenous pyelogram was proposed as
a screening test for clinically significant renal artery stenosis in
the early 1960s [18]. Recent re-evaluation of this test has
demonstrated that the number of false-positives and false-
negatives makes it an unreliable indicator even for unilateral
renovaseular hypertension [19]. Moreover, the diagnostic use-
fulness of this test in patients with ischemie renal disease
secondary to bilateral renovascular disease is minimal. An
intravenous pyelogram thus is not primarily indicated in a
diagnostic evaluation for isehemic renal disease. Not uncom-
monly, however, patients are referred in whom this test already
has been performed. In these patients, anatomic data provided
by the test (such as the presence of one or two functioning
kidneys, or a major discrepancy in renal size) are helpful.
Renal ultrasound examination falls into the same category as
the rapid-sequence intravenous pyelogram. It is not directly
helpful, nor is it primarily indicated in the evaluation of patients
for ischemic renal disease. However, many of these patients
will have been evaluated for azotemia and will have had a renal
ultrasound examination to exclude hydronephrosis; the test
sometimes provides useful anatomic information. The absence
of a kidney, the presence of two kidneys with one substantially
smaller than the other, and the demonstration of bilaterally
small kidneys are observations that should lead to further
diagnostic workup. None of these findings are specific for
ischemic renal disease, however. Indeed, it is not uncommon
for azotemic patients with 2 normal-sized kidneys on ultrasound
to experience significant improvement in renal function follow-
ing repair of renal artery stenoses.
Isotopic renal blood flow and renal function scans have been
evaluated extensively as a noninvasive means for diagnosing
renovascular hypertension [20—26]. As a screening test for
renovascular disease producing hypertension, the isotope
renogram probably is at least as sensitive as the IVP, but it also
suffers from a relative lack of specificity. Nonvaseular disor-
ders, such as chronic glonterular disease and renal tubular
disorders, can produce abnormalities similar to those seen in
renal artery stenosis. The sensitivity and specificity are some-
what improved by performing the isotope renogram after ad-
ministration of an angiotensin-converting-enzyme inhibitor
[27—29]. The "captopril renogram" is based on the observation
that, in patients with unilateral renal artery stenosis, captopril
administration produces a reduction of excretory function in the
affected kidney. Significant changes occur in the time-activity
curves of the affected kidney after a single oral dose of
eaptopril. These abnormalities are reversed when the renal
artery stenosis is corrected [28]. Isotopic renography some-
times is useful in screening for renovascular hypertension
associated with unilateral renal artery disease, but studies have
demonstrated its lack of sensitivity and specificity in the pres-
ence of bilateral renal vascular disease [21, 26].
Although quantitative isotopic renography probably will not
prove useful in the diagnosis of ischemie renal disease, it likely
will be valuable before and after operation (or angioplasty) as a
noninvasive method of following patency of the repaired renal
circulation. This suggestion will have to be studied prospec-
tively, but it has support from recently published studies in
patients treated with surgery or angioplasty for renovascular
hypertension [30—32].
Angiography is the preferred diagnostic method with respect
to evaluation of the anatomy of the renal circulation. Three
major techniques are available. These include intravenous
digital-subtraction and intra-arterial digital-subtraction angiog-
raphy, and standard aortography with selective renal arteriog-
raphy. The intravenous digital-subtraction angiogram (IV-DSA)
has been used extensively as a screening test for unilateral renal
artery stenosis in the diagnosis of renovaseular hypertension
[33—35] and although it has some advantages compared with
conventional arteriography (convenience, low cost, and lower
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risk), it does have disadvantages. First, distal arterial anatomy
is not well visualized with IV-DSA. Second, IV-DSA is suscep-
tible to motion artifacts. Finally, the IV-DSA often is
uninterpretable for technical reasons including obesity, conges-
tive heart failure, overlying bowel gas, or simply poor visual-
ization of the renal arteries. This lack of success is reported in
7% to 9% of examinations [34]. I do not believe that the IV-DSA
should be used as a primary test for diagnosing ischemic renal
disease, but it might prove useful in postoperative or post-
angioplasty followup evaluation of the renal circulation [36].
Intra-arterial digital-subtraction angiography (IA-DSA) also
has been used to diagnose renal artery stenosis. This technique
is superior to IV-DSA in that technically better images of the
renal arteries usually are obtained. Also, IA-DSA has certain
advaniages over standard arteriography: it can be accomplished
with about 15% of the contrast material required for conven-
tional arteriography; it utilizes a smaller catheter size; the
patient experiences less discomfort because a dilute contrast
medium is utilized; and the duration of the procedure generally
is shorter [37—39].
Intra-arterial digital-subtraction angiography likely will be-
come the preferred contrast technique in the evaluation both of
patients with renovascular hypertension as well as those with
ischemic renal disease, but conventional renal arteriography
currently is the only procedure that can consistently provide
complete information about the renal circulation and the pres-
ence or absence of collateral blood supply to the kidney. With
conventional angiography, the preferred technique involves
percutaneous puncture of the femoral artery and catheterization
of the abdominal aorta with aortography to define the origin and
number of the renal arteries. This procedure is followed by
selective catheterization of the renal arteries. A complete study
involves not only AP films, but also oblique views, especially to
define the origin of the right renal artery.
The major concern regarding the liberal use of angiography
for diagnosing ischemic renal disease is the risk of acute renal
dysfunction associated with the use of contrast media. It is
beyond the scope of this presentation to address this clinically
important phenomenon in detail, but many patients undergoing
angiography develop acute renal dysfunction of varying sever-
ity [40—43]. Reported incidences of renal failure range from
approximately 1% to 40%, the latter being reported in high-risk
groups [40—43]. The risk of renal failure increases as the dose of
contrast material increases and with patient dehydration. Ob-
viously, the minimum amount of contrast material should be
used and patients should not be dehydrated prior to the proce-
dure. Certain high-risk patients, for example, elderly patients
with compromised renal function (a typical description of
patients with ischemic renal disease), should be hydrated prior
to the procedure, preferably with intravenous saline. Unless the
patient has oliguric renal failure or suffers from intravascular
volume expansion, it is best to induce a saline diuresis. The goal
should be to maintain a urine output of 150 mI/hour or greater
for at least 2 hours prior to and 6 hours after the procedure. In
addition to the risk4 of contrast-induced renal failure, both
IA-DSA and regulatangiography are associated with the risk of
atheroembolic complications.
Peripheral renin measurements have been proposed as a
useful tool in the diagnosis of renovascular hypertension [1],
especially when coupled with induced sodium depletion or
administration of an angiotensin-converting-enzyme inhibitor
[44—47]. Plasma-renin activity (PRA), measured after the ad-
ministration of diuretics (so-called "stimulated" PRA) has been
proposed as a useful screening test for renovascular hyperten-
sion, but the usefulness of unstimulated or stimulated PRA in
bilateral renal vascular disease is limited. Indeed, the expansion
of intravascular volume that commonly occurs in bilateral renal
artery stenosis decreases or suppresses plasma renin activity
[48]. In fact, although the plasma renin activity, measured after
its stimulation by captopril, was highly sensitive and specific in
a retrospective analysis of a large number of patients with
hypertension and a normal serum creatinine level [47], the
sensitivity and specificity of the test were only 79% and 69%
respectively in identifying renovascular hypertension in azo-
temic patients. These data do not address the sensitivity and
specificity of plasma renin activity in the patients known to
have ischemic renal disease as the cause of their azotemia, but
the information suggests that this test will not be useful in
ischemic renal disease.
Determination of renal-vein-renin levels has been a major
diagnostic tool in the evaluation of patients suspected of having
renovascular hypertension [48—52]. Just as with peripheral-vein
renin levels, renal vein renins also have been determined after
administration of converting enzyme inhibitors [53—55]. In
contrast to the relatively high predictive value of the renal-vein
renin determination (expressed in various ratios) in unilateral
renovascular disease, renal-vein-renin determinations are not
helpful in patients with bilateral renal artery stenosis and
hypertension [56]. With respect to predicting the success of
revascularization in improving or curing the hypertension,
renal-vein-renin determinations in patients with bilateral renal
artery stenosis have an unacceptably high false-negative rate,
approximately 33%. When azotemia and hypertension are
present, volume expansion probably is partly responsible for
this high false-negative rate. Renal-vein-renin ratios might be
helpful in patients with ischemic renal disease in identifying
which kidney should be the first target for revascularization.
Thus, if patients have evidence of bilateral renal vascular
disease on angiography, it might be best to revascularize the
kidney with the highest renal-vein-renin ratio first. This sugges-
tion requires prospective evaluation.
In the diagnosis of functionally significant renal artery steno-
sis resulting in hypertension, the renal-vein renin determination
generally has replaced split-function studies. Almost no indica-
tions for performing split-function studies currently exist in an
evaluation for renovascular hypertension, but split-function
studies occasionally are useful in a patient with bilateral renal
vascular disease and renal dysfunction. Split-function studies
usually include the performance of 3 timed collections of
ureteral urine from each kidney, with measurement of urine
flow rate, urine creatinine concentration, urine paraaminohip-
purate (PAH) concentration (the patient having received a
loading dose and constant infusion of PAH during the study),
and urine osmolality. The criteria utilized for determining the
presence of significant unilateral ischemic disease (that is,
differential function between the kidneys) cannot be applied to
patients with bilateral disease. Rather, the absolute renal
plasma flow rate and GFR as calculated from the PAH and
creatinine clearances can provide useful information regarding
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Table 4. Treatment options in isehemic renal disease
1. Conservative therapy
2. Percutaneous transluminal
angioplasty
3. Surgical revascularization
a. Aortorenal bypass
b. Spleno-, hepato-, ilio-renal bypass
c. Endarterectomy
possible strategies for revascularization, that is, which kidney
should receive attention, or which kidney should be operated
on first.
One last test depends on the fact that the presence of
significant, bilateral, renal vascular lesions can be associated
with an acute rise in BUN and creatinine when blood pressure
is lowered acutely [5—17]. Intravenous sodium nitroprusside
infusion, monitoring of blood pressure, and determining indi-
vidual kidney GFR have been proposed as a means of detecting
ischemic renal disease. A significant reduction in GFR (or renal
plasma flow) in one or both kidneys in response to blood
pressure reduction may be useful in helping one decide which
kidney to revascularize first. An example is given in Figure 2, in
which the GFR and renal plasma flow data relate to the right
kidney. The left kidney in this patient had a baseline GFR of
less than 5 mi/minute. Based on this information, the right
kidney was revaseularized, thus protecting its GFR from sig-
nificant deterioration during medical therapy for hypertension.
It is unlikely that this test will be applied extensively in the
evaluation of patients with ischemic renal disease because of its
invasive nature; it is more likely that patients with ischemic
renal disease will be unintentionally diagnosed during pharma-
cologic therapy directed at controlling their hypertension. Cir-
cumstances might arise, however, in which such functional
"stress" tests will help in deciding revascularization strategy.
Having reviewed the diagnostic tests available to search for
ischemic renal disease, I would like to make one more comment
about the functional significance of a vascular lesion before
discussing the treatment options in this disorder. As I indicated,
angiographic demonstration of a vascular lesion is not always
proof of functional significance of that lesion. Of course,
demonstration of complete renal artery occlusion with or with-
out collaterals to the affected kidney is diagnostic for absence of
significant excretory function for that kidney. As I will discuss
subsequently, however, the reversibility of the renal function
loss cannot be predicted by the angiographic picture. Similarly,
the unequivocal demonstration of almost complete (that is,
greater than 90%) occlusion of the renal artery confidently can
be assumed to result in a significant reduction in renal function.
What about vascular lesions of lesser severity? When is the
vascular stenosis critical? A consensus exists that 70% or
greater stenosis of the main renal artery is associated with a
significant reduction in renal plasma flow and GFR [23, 57—601.
Another criterion for a functionally important vascular lesion is
the demonstration of a significant pressure gradient across the
lesion. Reduced renal plasma flow and GFR and an associated
reduction in urine flow rate and sodium excretion occur when a
gradient of at least 40 mm Hg exists across the lesion [6lJ.
Table 5. Functional results following surgical revascularization of
poorly functioning kidney?
# of kidneys
Pre-op UFR
(mi/mm)
Post-op OFR
(mi/mm) P
5 3,4 36.2 <0.02
9 16.0 32.0 <0.01
9 25.0 30.0 <0.05
a From Ref. 73.
Therapeutic strategies in ischemic renal disease
Table 4 lists treatment alternatives in ischemic renal disease.
Morbidity and mortality rates from surgical revascularization
have fallen significantly over the past 2 decades. In addition,
angioplasty of atherosclerotic lesions has provided another
important therapeutic option. As a result, the first option listed
in Table 4, conservative therapy with medical management of
blood pressure only, should be an uncommon choice. Certainly
upon investigation some patients with ischemic renal disease
will be found not to be candidates for nngioplasty nor for
operation. In some of these patients, the clinician must rely on
conservative medical management and accept a high probability
that renal function will deteriorate sufficiently to produce end-
stage renal disease. Fortunately, however, surgery and angio-
plasty are now viable alternatives.
Many reports describe the application of surgery and percu-
taneous transluminal angioplasty to the treatment of patients
with renovascular hypertension. This information has been
critically analyzed in a previous Nephrology Forum [1]. Here I
will review only those studies that deal with surgical revascu-
larization or angioplasty for preservation or improvement of
renal function.
Surgical revascularization. No prospective studies have eval-
uated the outcome of patients randomized to surgical versus
angioplastic treatment for ischemic renal disease, but a number
of reports have dealt with one or the other approach to patients
with azotemia secondary to ischemic renal disease. Since the
first publication on surgical intervention for isehemic disease
[62J, many studies have documented various degrees of success
in reversing azotemia and managing hypertension in the
azotemic patient with ischemic renal disease [17, 63—891. This
incomplete list of references presents information on hundreds
of patients in whom a surgical approach was taken to restore
renal function. In one important study [73], renal vascular
surgery was performed mainly to treat hypertension, but be-
cause patients had undergone both pre- and postoperative split
renal-function studies, data were available on the ischemic
kidneys' functional response to revascularization. Some of
these patients had significant but mild azotemia (that is, serum
creatinine less than 2.6 mg/dl). The pre- and postoperative
GFRs are illustrated in Table 5. The kidneys with the lowest
pre-operative GFR had the greatest improvement. This study is
important for several reasons: (1) It documents the sometimes
dramatic increase in GFR that can be obtained with revascu-
larization; (2) it provides solid evidence that significant renal
function can be restored in kidneys served by totally occluded
main renal arteries; (3) it illustrates the successful application,
at least for clinical investigation, of split renal-function studies;
and (4) it underscores the concept that management of hyper-
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Table 6. Results of surgical revascularization for ischemic renal disease
Number of
patients
Mean
age
Operative
deaths
Renal function Mean followup
Improved
Pre-op GFR
Stable
or
Worse
Post-op GFR Survival
Time
(months) Ref.
67 (1975—1980)
94 (1981—1984)
611
55 1 >2% 58% 31% 11% 89% 39 89
23 61 4% 65% 21% 14% 78% 24 82
20 59 15%a 28 cc/mm — 45 cc/mm 80% 29 85
64" 58 — 60% 40% 86
a 3 patients died within 30 days of surgery.
b 58 patients with atherosclerotic disease, 6 patients with fibromuscular dysplasia.
C Only patients with successful operative procedures were included, and long-term followup was not included.
Number alive
(Mean
Number of survival,
patients months)
3 (29.5)
6 (58.2)
Number dead
(Mean
survival.
months)
13 (8.7)
2 (96)
tension in renal vascular disease with a poorly functioning
kidney does not require nephrectomy.
Studies published over the last several years confirm the
relatively high success rate of surgery in preserving, and
especially in improving, renal function in patients with ischemic
renal disease. Table 6 summarizes results of 4 surgical studies
reporting on 268 patients [82, 85, 86, 89]. The similarities among
these studies are remarkable. The mean age of the patients was
similar, as was the outcome of renal function after surgery.
Also, fully one-third of the kidneys operated on had totally
occluded arteries. Indeed, a number of these totally occluded
kidneys were relatively small, that is, less than 8 cm in length.
Operative mortality ranged from 2% to 15%. Surgical attack on
kidneys with total occlusion of the renal artery deserves addi-
tional comment.
A substantial number of the studies dealing with surgical
treatment of ischemic renal disease address the specific clinical
circumstance in which one finds either total occlusion of the
renal artery to a solitary kidney or total occlusion of a renal
artery to one kidney associated with contralateral, significant
renal artery stenosis [65, 68, 69, 72, 74—79, 84, 88]. It is well
known that the kidney can develop sufficient collateral blood
flow to maintain viability and also to maintain some function
[90]. These collaterals can come from the adrenal circulation,
the lumbar arteries, and the ureteric arteries. Sufficient time for
the development of these collaterals in the setting of atheroscle-
rotic renal vascular disease allows for complete occlusion of the
main renal artery without infarction and death of the involved
kidney. Therefore it should not be surprising that a substantial
number of patients with significant azotemia secondary to
ischemic renal disease have total occlusion of at least one renal
artery. The studies I have cited support the use of an aggressive
approach to restoring renal function in kidneys with total
occlusion of the renal artery. Unfortunately there are no
predictors sufficiently sensitive and specific to dictate whether a
kidney with an occluded artery should be revascularized. The
predictors listed in Table 7 thus serve only as guidelines. I
believe it is likely, however, that the presence of predictors 1
through 4 in Table 7 will predict success in restoration of
significant renal function.
Although there is unequivocal evidence that surgical revas-
cularization can improve and stabilize renal function in patients
with ischemic renal disease, we have little idea of how many
patients we can prevent from requiring dialysis and for how
long. Indeed, no rigorous information is available on the com-
parative survival of patients with surgical revascularization as
compared with patients with similar disease managed medi-
cally. In 1984, however, Novick et al published uncontrolled
observations suggesting that surgical correction of ischemic
renal disease, at least in patients with end-stage renal failure,
sometimes improves survival (Table 8) [831. Twenty-five dialy-
sis patients with angiographically proven ischemic renal disease
were either revascularized (8 patients) or maintained on dialysis
(17 patients). Surgery was performed on the patients whose
angiographic evaluations suggested salvageable renal function.
In the 17 patients who were maintained on dialysis, 13 patients
died after a mean survival of 8.7 months. The most common
cause of death was myocardial infarction (6 patients). In the 8
patients who underwent surgery, all the operations were suc-
cessful; all the patients experienced significant recovery of
renal function and required no further dialysis. Of the 8 pa-
tients, 6 were alive at the time of report; mean survival time
exceeded 58 months. The 2 patients who died (of myocardial
infarction and refractory congestive heart failure) survived, on
average, 96 months. Although we must be careful not to
extrapolate from this uncontrolled study, the results are pro-
vocative, and they suggest that further prospective information
Table 7. Predictors of successful restoration of renal function in
kidneys supplied by a totally occluded renal artery
1. Nephrogram (late) on angiography
2. Collateral circulation on angiography
3. Renal size >9.0 cm on ultrasound or angiography
4. Renal-vein-renin ratio (renal vein vs. inferior vena cava) >2.0
5. Function (differential concentration of urine) on split-function
studies
6. Spontaneous backbleeding on arteriotomy during surgery
7. Viable nephrons on biopsy
Table 8. Survival of 25 patients with end-stage renal disease caused
by atherosclerotic renovascular diseasea
a From Ref. 83.
Chronic dialysis 17
Surgical revascularization 8
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a Adapted from Ref. 104.
should be sought not only about renal functional results but also
about survival.
Percutaneous transluminal renal angioplasty (PTRA). Percu-
taneous angioplasty has been applied to atherosclerotic lesions
in the renal artery for 10 years [91]. Since the original report, a
number of publications have outlined the clinical experience
with PTRA, mostly in the treatment of renovascular hyperten-
sion, but with some information on the renal functional re-
sponses to this procedure [92—1061.
With respect to the role of PTRA in improving renal failure,
a 1980 report presented information on 12 patients with reno-
vascular hypertension and renal failure who underwent PTRA
[921. In 2 patients, renal function improved; in 6, renal function
stabilized. Subsequently, a report of PTRA specifically directed
towards improving renal function further strengthened the
notion that this technique could be an alternative form of
therapy in ischemic renal disease [99]. In this study, performed
by Drs. Madias, Kwon, and Millan here at the New England
Medical Center, all 12 patients who underwent PTRA had both
a prior major reduction in GFR as well as severe hypertension.
Interestingly, 10 of the patients had significant atherosclerotic
renovascular stenosis in a solitary functioning kidney, and 2
patients had bilateral atherosclerosis. In these 12 patients, 13
vascular lesions were attacked, and 11 were successfully di-
lated. Blood pressure significantly improved in all but one
patient. In total, 6 important complications developed, includ-
ing 3 episodes of nonoliguric acute renal failure, a thrombotic
occlusion of a renal artery, a tear of the balloon segment of the
catheter (requiring femoral arteriotomy), and one episode of
gastrointestinal bleeding. With respect to renal function, in 7 of
the 11 patients in whom a technical success was achieved, there
was either stabilization or modest improvement, as assessed by
measurements of serum creatinine.
More recent studies on PTRA have elicited several important
observations regarding its success [99—106]. Most of the data
available on technical success rate and long-term patency have
been derived from studies applying PTRA to patients treated for
renovascular hypertension, however, not primarily for preser-
vation of renal function. Similar data are needed for patients
undergoing PTRA for preservation of renal function; ideally,
comparison of such patients in a prospective randomized way
with patients undergoing surgical revascularization for the same
reason should be carried out.
With respect to atherosclerotic lesions, the technical success
rate depends on the location and diffuseness of the lesion [1021.
Atherosclerotic lesions at the origin of the renal artery are in
reality lesions of the aorta and respond poorly to angioplasty. A
technical success rate of less than 25% can be expected with an
ostial lesion [102]. Similarly, total occlusion of the renal artery
is associated with a low technical success rate. In contrast,
well-localized atherosclerotic lesions in the first and second
third of the main renal artery are associated with an 80% to 95%
initial technical success rate when experienced angiographers
perform the procedure [104] (Table 9). The re-stenosis rate is
10% to 30%, and the majority of these stenotic vessels can be
successfully re-dilated [104]. Another important observation
from recent studies is that technical success in PTRA of
atherosclerotic lesions depends on dilation of the lesion with a
balloon that can be inflated to a diameter approximately 1 mm
greater than the normal lumen diameter of the renal artery
[102—104], In experienced hands, the technical success rate is
95%, with a 90% patency rate at a mean followup of 4.5 years
[104].
These recent studies with PTRA, in addition to providing
important information on the improved technique and success
rate, also detail the complications that can be encountered [102,
106]. Major complications have been reported in 3% to 10% of
patients (Table 10). Although in experienced hands the major
complication requiring surgical intervention (renal artery rup-
ture and hemorrhage) is very uncommon, the possibility of this
complication has led many nephrologists and interventional
angiographers to insist that surgical backup be available for all
procedures. In fact, it is appropriate in the management of these
patients that a team approach be taken, with the team consisting
of the nephrologist or internist, the surgeon, and the angi-
ographer.
Questions and answers
DR. PAUL KURTIN (Chief, Division of Pediatric Nephrology,
New England Medical Center, Boston, Massachusetts): What
is the incidence of contrast-induced acute renal failure in your
patients, and how do you screen patients prior to angiography?
DR. JAcOBSON: In evaluating these patients and looking at the
literature, the incidence of significant, acute, presumably con-
trast-induced, renal failure is between 2% and 22%. There
appears to be a higher incidence in patients who have higher
serum creatinine levels prior to the radiographic procedure.
Hypertension and renal insufficiency put one at greater risk for
contrast-induced acute renal failure. Intravenous pyelograms
and intravenous digital subtraction angiograms appear to result
in the highest incidence of contrast-induced acute renal failure,
probably because the volume of contrast medium used is large.
Although no published data prove my point, it appears that
Table 9. Initial success and followup patency rate documented by
arteriography after renal artery angioplastya
Initial Patency Mean
No. of success rate followup Reference
patients (%) (%) (years) no.
68 85 81 3 107
17 94 75 1 108
54 96 70 — 109
70 93 7I .05 110
101 79 — — til
90 95 90 4,5 104
Table 10. Complications of transluminal angioplasty of renal arteries
Major (3%—10%) Minor
1)
2)
3)
4)
5)
6)
Rupture of renal artery
Dissection of the renal or ac-
cess artery
Renal artery thrombosis
Contrast-induced ARF requir-
ing dialysis
Peripheral artery emboliza-
tion
Mortality ( 1%)
1)
2)
3)
4)
Hemorrhage at puncture site
Renal artery spasm
Rupture of the balloon
Transient mild ARF not re-
quiring dialysis
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intra-arterial digital subtraction angiography is less likely to
cause contrast-induced acute renal failure.
With respect to the second point, how do we screen patients
prior to angiography? I have tried to argue that there is no good
way to accomplish this. Trying to identify the overall clinical
circumstance as one in which ischemic disease may be playing
a role is the best approach. Certainly there are some clues. The
patient who has classic accelerated hypertension—frequently a
young black patient who presents with accelerated hyperten-
sion and a rising serum creatinine, but infrequently one with
bilateral renal vascular disease—can be excluded from angiog-
raphy. Although it hasn't been well studied and reported in the
literature, another potentially important screening test would be
measurement of 24-hour urine protein excretion. Renal failure
secondary to glomerular disease may be associated with a
protein excretion rate greater than 1 g/24 hr, whereas ischemic
renal disease would result in lesser rates of protein excretion. In
addition, microscopic examination of the urine sediment might
be helpful in identifying patients whose renal failure is more
likely to be glomerular in origin.
There are, however, exceptions to this general rule. Two that
come to mind are diabetic patients who may have proteinuria
secondary to diabetic glomerulosclerosis with superimposed
atherosclerotic renal vascular disease, and patients with athero-
sclerotic renal vascular disease and rapidly accelerating hyper-
tension that produces glomerular injury.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I am interested in
a better estimate of the frequency of bilateral renal artery
stenosis as a cause of total renal failure. I did not hear any such
data in your presentation. Has anyone taken 100 or so consec-
utive patients presenting with end-stage renal disease and
looked for bilateral renal artery stenosis?
DR. JACOBSON: Not that I'm aware of. But let's make some
calculations. If 600,000 patients in the United States have renal
vascular disease (a reasonable estimate based solely on the
incidence of renovascular hypertension), if most of those pa-
tients currently are not operated on (that is also true), and if
there is a significant incidence (20% to 40%) of progression of
the vascular disease to become bilateral, one could predict that
60,000 to 120,000 patients in the United States have progressive
azotemia on the basis of bilateral ischemic disease. If only 5%
of these patients reach end-stage renal disease annually, 3000 to
6000 new patients with ESRD per year would carry this
diagnosis.
DR. I-IARRINGTON: Would you want to study every patient
who comes in for dialysis?
DR. JAcoBsoN: No, I think what we need to do now is to find
out how better to identify the patients whom we should study
with a renal arteriogram. Keep in mind that certain clinical
information should allow us currently to determine whether
patients fit into the clinical presentation prototypes I mentioned
(Table 1).
DR. HARRINGTON: What criteria do you currently use to
identify patients who have bilateral renal artery stenosis?
DR. JACOBSON: If the patient's history includes hypertension
that is not well controlled, if there is no history of long-term
diabetes (that is, greater than 7 to 10 years), if the patient is over
the age of 55 years, if the patient has a 24-hour urine protein
excretion under 1 g, and if the patient has no other explanation
for azotemia, I use an intra-arterial digital subtraction angio-
gram.
DR. HARRINOTON: It seems that we need to perform a
prospective study to define the incidence of this cause of ESRD
and to define criteria for studying patients with angiography.
DR. JAcoBsoN: I agree. The incidence of progression from
atherosclerotic disease to renal failure should be an answerable
question.
DR. MICHAEL MADALO (Division of Nephrology, New En-
gland Medical Center): You indicated that every patient with an
increasing serum creatinine and moderate hypertension should
be evaluated for the presence of correctable renovascular
disease. This is a large group of patients, and little information
is available about them. Specifically, what is the incidence of
renovascular disease in this population? Are the risks of angio-
gram and/or angioplasty higher in these patients than in a more
selected group? What is the likelihood of anatomic success?
What is the likelihood that there will be a beneficial outcome in
the group with an anatomically successful result? What is the
likelihood that angiogram and/or angioplasty will accelerate the
progression of renal disease? Should these issues be addressed
prior to advocating angiogram and/or angioplasty for the pa-
tients with hypertension and progressive renal failure?
DR. JACOBSON: That is why there is a question mark at the
end of the title to this presentation. We at Vanderbilt are a
liberal group. Your questions are very much to the point. The
data to answer them adequately simply are not available. Not
all patients with hypertension and a rising creatinine level
should have angiography. Every effort must be made to exclude
other causes of azotemia. In practice, primary glomerular
disease and glomerular disease secondary to systemic disorders
such as diabetes and collagen-vascular diseases frequently are
diagnosed as the cause of azotemia and hypertension. Probably
no more than one-third of the patients who develop end-stage
renal disease are likely to be serious candidates for ischemic
renal disease. Even in a large ESRD program, this amounts to
no more than 20 to 25 patients per year. Obviously, and to
answer your question more directly, if we wish to diagnose this
disorder prior to the patient developing ESRD, larger numbers
of patients need to be investigated. Presently we are identifying
the "tip of the iceberg." We are identifying patients who, by no
design of ours, demonstrate significant ischemia when we treat
their hypertension with angiotensin-converting-enzyme inhibi-
tors.
That brings us to the second important point you raised: after
you define the anatomy, how do you decide who should
undergo angioplasty and who should be operated on? How do
you answer the question, if I subject this patient to angioplasty
or operation, am I going to produce an ultimate outcome with
respect to renal function preservation and survival that is
different than that if only the hypertension alone were man-
aged? We need a prospective study to look at that. We simply
do not know what patient survival or kidney survival will be.
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center): I generally share your view
about the limited predictive power of various tests in diagnosing
hemodynamically significant renovascular disease. Most impor-
tant, as you pointed out, most of these tests have been
evaluated with regard to their ability to prognosticate the
impact of revascularization on hypertension, but not on renal
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dysfunction. Concerning the "captopril test," do you know of
any prospective application of the criteria reported in the
retrospective analysis you cited 1471?
DR. JACOBSON: The literature supports that this test result is
something you can reverse if you fix the lesion. The test may be
specific for renal vascular disease amenable to surgery or
angioplasty. Whether it is a sensitive test has not been ad-
dressed. In short, we do not have the benefit of a prospective
application of the captopril or nitroprusside test.
DR. MADIA5: Along the same lines, I agree with your
assessment that the sensitivity and specificity of radionuclide
renal scanning for renovascular disease are such that it is an
unsatisfactory diagnostic tool. In our own practice, we have
restricted its use virtually exclusively for evaluating the possi-
bility of renal infarction as a complication of angioplasty and for
followup of the patency of revascularized renal circulation, I
believe, however, that you were excessively generous in your
assessment of the value of the renal-vein-renin ratio. Several
analyses of large series of patients with renovascular hyperten-
sion have concluded that although the test has a strong positive
predictive value, it also has a staggering false-negative rate on
the order of 60% [112], Do you use the renal-vein-renin ratio
routinely as a guide to your revascularization approach in
bilateral renovascular disease and renal dysfunction?
DR. JAcoBsoN: I am glad you are making this point because
I don't think that the renal-vein-renin ratio makes much differ-
ence in bilateral disease. The point is that with bilateral disease
one does not necessarily find lateralization. Both renal veins
can demonstrate renin concentrations greater than those in the
inferior vena cava (IVC). A high renal vein-to-IVC renin ratio
might be a good predictor for restoration of renal function. I
might add that, as far as the split renal function studies go, there
are reports in the literature of significant improvement in
glomerular filtration rate in kidneys that had chronically oc-
cluded renal arteries and virtually no clearance [68, 69]. Possi-
bly renal-vein-renin levels in such kidneys might be helpful in
deciding on revascularization.
DR. MAmAs: Given the information currently available,
which in your judgment is the best predictor of a favorable renal
functional outcome following revascularization?
DR. JACOn5ON: I would not want to pick a single best
predictor. I think the best predictor of successful outcome is
probably bilateral disease with stenosis of greater than 75% in
both arteries or total occlusion bn one side and a significant,
greater than 70% to 75%, stenosis on the other side. That is
probably what we have the most data on. I do not think that any
one test has been studied well enough to give us reliable
information.
DR. VICTOR G. MILLAN (Chief of Cardiovascular and
Interventional Radiology, New England Medical Center): Soon
after Dr. Madias and I performed the first renal angioplasty in
North America in February of 1978, we understood that im-
provement in renal function was our primary objective with
PTRA. Any ensuing amelioration of hypertension was a bonus
that was gladly accepted. The benefits of PTRA are high; the
risks are low.
Intra-arterial angiography, whether recorded digitally or on
conventional film, is the only reliable method for diagnosing
renovascular disease and determining what anatomic treatment
is indicated. In good hands, the risk of contrast-induced acute
tubular necrosis should be 2% to 3%. In my experience, digital
intravenous angiograpby is neither accurate nor benign for
screening most patients.
I am delighted that you are focusing attention on renal
ischemia. Like the heart and the lower extremities before it, the
"claudicating kidney" now deserves early recognition and the
benefit of angioplasty.
DR. JACOBSON: I am pleased to hear your thoughts on this
topic and gratified that we have come to similar conclusions.
The concept that atherosclerosis of the renal artery can cause
functional changes and not only hypertension, and that the
renal artery, like other major vessels, is amenable to angio-
plasty has not yet achieved widespread acceptance.
DR. MAmAs: We have reported encouraging experience with
long-term stabilization of renal function following technically
successful angioplasty; our patients included those with reno-
vascular stenosis in a solitary functioning kidney and moder-
ately severe renal insufficiency [113].
DR. JACOBSON: Your results are encouraging, and a full
report on these patients will be a significant contribution.
DR. HARRINCTON: You referred to Dr. Novick and associ-
ates' studies at the Cleveland Clinic. Eight patients were
operated on, and 17 were not operated on. The difference in
outcome was striking. I suspect that the difference in outcome
reflects a difference in selection. How did these investigators
determine who would be operated on and who would not?
DR. JACOBSON: I did not have a chance to ask them how they
selected those patients. They did not present enough detail in
the original paper for us to determine why those particular 8
patients were operated on and the other 17 not.
DR. RICHARD KOPELMAN (General Medicine Division, New
England Medical Center): To screen for physiologically signif-
icant renal artery lesions, some investigators have reported on
the use of renal scans following administration of a converting
enzyme inhibitor. Do you have any experience with this ap-
proach to screening patients for renovascular hypertension?
Da. JACOnS0N: My personal experience is not sufficient to
make a strong claim for or against this method. To advocate it
as a useful screening test, solid information on its sensitivity
and specificity will be needed. The same is true for its potential
in diagnosing ischemic renal disease. With respect to the latter,
I suspect that it will not be a useful test.
DR. KOPELMAN: Have you studied your series of digital
subtraction angiograms to determine how good your clinical
suspicion of renovascular disease has been, and to find out the
yield of these studies?
DR. JACoBSoN: I have not looked at them rigorously. My
personal "batting average," that is, the percentage of patients
studied angiographically who have isehemic renal disease as
assessed by successful intervention, is definitely less than 50%
and probably more like 25% to 33%. I would like to have data
that would allow me to conclude whether this yield is good or
bad. Clearly, a certain number of studies that do not show
ischemic renal disease must be performed. Let me illustrate
with a recent patient. Two months ago a 64-year-old white male
was referred to me for oliguric renal failure of unknown
duration. The patient had a history of rheumatoid arthritis and
did have chronic classic deforming arthritis. His urine sediment
was unremarkable and the 24-hour urine protein excretion was
less than 1 g. He had a significant history of aortoiliac athero-
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sclerotic vascular disease and had had an aortoiliac graft several
years before. He also had a history of modest, not-difficult-to-
control, hypertension. Renal ultrasound demonstrated no ob-
struction and bilaterally low-normal renal size. A renal scan
demonstrated almost no flow bilaterally. With this information
we were very suspicious of ischemic renal disease. However,
digital subtraction angiography demonstrated perfectly smooth,
open renal arteries bilaterally. Renal biopsy demonstrated
advanced crescentic glomerulonephritis.
DR. MADIAS: Although I fully agree with your contention that
ischemic renal disease is a potentially reversible cause of
azotemia that has been relatively overlooked, I want to re-
emphasize the considerable risks associated with either of the
revascularization approaches. As you pointed out, frequently
these patients have extensive cardiovascular and cerebrovas-
cular disease that imposes severe limitation on their life expect-
ancy. Mortality rates as high as 3% have been reported follow-
ing angioplasty [1061. Some contemporary series still report
mortality rates of 10% to 17% in patients with diffuse athero-
sclerotic disease following renovascular surgery [81, 1141. It is
notable that the group that has reported the lowest mortality
rate for renal revascularization in the elderly (2%) subjected
their patients to an exhaustive evaluation and correction of
coexisting coronary and/or cerebrovascular disease prior to
renovascular intervention [891. In my opinion, a restrained
approach is prudent for high-surgical-risk patients.
Da. JACOBSON: I agree. Atherosclerotic renal vascular dis-
ease is not an isolated syndrome. The majority of these patients
have the same advanced vascular disease in other critical
(cerebrovascular and coronary) parts of the circulation. Evalu-
ation and, when indicated, correction of vascular disease else-
where sometimes improves the operative risk for surgical renal
revascularization. Finally, we should emphasize that preven-
tive measures, that is, attempts to forestall atherosclerosis in
general, are likely to benefit the kidney as well as the heart and
the brain.
Reprint requests to Dr. H. Jacobson, Division of Nephrology, Room
3223 MCN, Vanderbilt University, Nashville, Tennessee 37232, USA
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